Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Antitope Ltd.. (1/24/13). "Press Release: Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.". Cambridge.

Organisations Organisation Antitope Ltd.
  Group Abzena (Group)
  Organisation 2 NeuroPhage Pharmaceuticals Inc.
  Today Proclara Biosciences Inc.
  Group Proclara Biosciences Inc.
Products Product Composite Protein™ deimmunisation technology
  Product 2 therapeutic protein
Index term Index term NeuroPhage–Antitope: drug development services, 201301– supply application of Composite Protein deimmunisation techn for therapeutic protein developm
Persons Person Baker, Matthew (Matt) (Antitope 201301 CEO + Co-founder)
  Person 2 Butt, Neil (Iontas 201804 CBO before Abzena + Antitope)
     


Antitope Ltd., UK ("Antitope") today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA ("NeuroPhage") for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply it's Composite Protein™ deimmunisation technology to a next generation treatment for neurodegenerative diseases.

"We are delighted to be working with such an innovative company as NeuroPhage," said Dr Matthew Baker, Chief Executive Officer and co-founder of Antitope, adding "This partnership utilises Antitope's expertise in engineering non-immunogenic proteins to complement NeuroPhage's innovations in developing novel therapeutics based on clearance of pathological protein aggregates."


About Antitope

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope's proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of proteins and humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For more information, please visit www.antitope.co.uk.or contact:

Antitope Ltd.
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190
Emai: info@antitope.co.uk


About NeuroPhage Parmaceuticals, Inc.

NeuroPhage is a biotechnology company focusing on a unique disease-modifying approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a team based in Cambridge, MA, USA, along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.

For more information, please visit www.neurophage.com or contact info@neurophage.com


Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: info@antitope.co.uk

Antitope Ltd (US)
5338 E Saguaro Place
Paradise Valley
AZ 85253
United States

Email: info@antitope.com

   
Record changed: 2018-07-07

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Abzena (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px




» top